Medical Updates Digest

The FDA approval adds major adverse cardiovascular event reduction to Mounjaro's glycemic and weight-loss benefits for high-risk type 2 diabetes...

A new report warns that Florida's Amendment 3 could reduce funding for hospital districts that care for the uninsured.

• Sarasota County Public...

This week’s FDA actions and deals stand out for their immediate clinical and commercial impact.

• Priovant’s Lisraya won approval as the first...

AI tools extract data from unstructured medical records to identify eligible clinical trial patients and surface care gaps in oncology practices. The...

This week's notices signal upcoming shifts in drug oversight and compliance.

• FDA seeks input on scheduling eight substances including...

• ELEGANT trial tests elacestrant versus standard therapy to cut recurrence risk in node-positive patients
• NOAX trial compares targeted lymph-node...

Clinical Trials Ontario has shifted patients from research participants to active partners in shaping trials and operations over the past decade.

-...

Michigan lawmakers unveiled bipartisan reforms to boost primary care amid widespread shortages, with 75 of 83 counties and nearly one-third of...

AstraZeneca and Ionis’s Wainua gene silencer suffered a surprise failure in a high-profile cardiovascular trial, attributed to patients also taking background therapies, which now complicates the path for RNA-based treatments in heart disease.

• Enhanced subsidies expired December 31, 2025, raising out-of-pocket premiums for many 2026 Marketplace enrollees.
• Core ACA rules on guaranteed...

The DOJ's June memo declaring Olmstead unenforceable has prompted it to vacate a Florida ruling, leaving families like Kayla Webb's without guaranteed...

Medicare generally does not cover medical expenses outside the United States, leaving seniors exposed during international trips.

• Nearly half of...

Free community nutrition classes like Dining with Diabetes give patients and families hands-on training in healthy meal prep, meal planning, and exercise to better manage blood glucose and lower complication risks.

Rusfertide (Mimrylo) delivers a first-of-its-kind, less-invasive option for polycythemia vera patients long reliant on frequent bloodletting to manage excess red blood cells and clot risks. The drug becomes available within 48 hours of approval.

Acarbose stands out as the only oral antidiabetes drug approved for prediabetes, cutting type 2 diabetes incidence by 36% while also lowering...

Nearly 80% of 23-year-olds already show cardiovascular-kidney-metabolic syndrome, with thicker artery walls tracking higher stages. Baseline checks...

Could association health plans lower premiums for self-employed workers while creating new coverage risks?

The Labor Department is drafting a rule to...

Wearable technology integrated into digital health ecosystems enables continuous and remote monitoring, supporting early event detection and tailored interventions.

Hospitals apply rigorous scrutiny to surgical robotics purchases, requiring published outcomes, comparative studies, regulatory clearance, and surgeon...

Oncology physical therapy requires advanced training to address cancer's unique effects on the body.

• Specialized focus accounts for fatigue, nerve...